Medical treatment of fibroids: <scp>FIGO</scp> best practice guidance

Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication. GnRH analogs are primarily indicated for the preoperative management of uterine fibroids, largely because of their unfavorable long-term adverse effect profile. The previously approved therapy with ulipristal acetate had to undergo extensive restrictions because of safety concerns. Nevertheless, there are additional medications that may be used in clinical practice. These include combined oral contraceptives, oral progestins, the levonorgestrel-releasing intrauterine system (LNG-IUS), and tranexamic acid. Although not specifically approved for the treatment of fibroids, these agents can reduce the intensity of bleeding in cases of heavy menstrual bleeding and thereby improve symptoms and lead to an improved quality of life for the patients.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecology & Obstetrics
Published
2025-09-10
DOI
https://doi.org/10.1002/ijgo.70497
Citations
2
Primary Topic
Uterine Myomas and Treatments
Type
article
Field-Weighted Citation Impact
4.11
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Medical treatment of fibroids: FIGO best practice guidance

Magdalena Zeppernick, Mary Ann Lumsden, Ivonne Díaz
2 citations
International Journal of Gynecology & Obstetrics
Uterine Myomas and Treatments
4.11
article

Medical treatment of fibroids: FIGO best practice guidance

Magdalena Zeppernick, Mary Ann Lumsden, Ivonne Díaz
article en
2 citations

Abstract

Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication. GnRH analogs are primarily indicated for the preoperative management of uterine fibroids, largely because of their unfavorable long-term adverse effect profile. The previously approved therapy with ulipristal acetate had to undergo extensive restrictions because of safety concerns. Nevertheless, there are additional medications that may be used in clinical practice. These include combined oral contraceptives, oral progestins, the levonorgestrel-releasing intrauterine system (LNG-IUS), and tranexamic acid. Although not specifically approved for the treatment of fibroids, these agents can reduce the intensity of bleeding in cases of heavy menstrual bleeding and thereby improve symptoms and lead to an improved quality of life for the patients.

International Journal of Gynecology & ObstetricsVol. 171(2)
Justus-Liebig-Universität Gießen (DE), Military University Nueva Granada (CO), University of Glasgow (GB)
Openalex Percentile: Top 6%
Uterine Myomas and Treatments
4.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.